Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Macrulin Cortecs Ltd.

J Luo1

  • 1Shaman Pharmaceuticals, 213 East Grand Avenue, South San Francisco, CA 94080-4812, USA. jian_luo@shaman.com

Idrugs : the Investigational Drugs Journal
|May 10, 2008
PubMed
Summary
This summary is machine-generated.

Macrulin, an oral insulin delivery system, effectively lowers blood glucose and increases insulin levels in type II diabetes patients. This novel approach demonstrated safety without hypoglycemia, even at high doses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-visualisation of cavum septi pellucidi: implication in prenatal diagnosis?

Insights into imaging·2013
Same author

Estimation of birth population-based perinatal-neonatal mortality and preterm rate in China from a regional survey in 2010.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·2013
Same author

Pinellia pedatisecta agglutinin interacts with the methylosome and induces cancer cell death.

Oncogenesis·2013
Same author

Transverse momentum distribution and nuclear modification factor of charged particles in p+Pb collisions at sqrt[s(NN)] = 5.02 TeV.

Physical review letters·2013
Same author

Numerical and experimental study of a high port-density WDM optical packet switch architecture for data centers.

Optics express·2013
Same author

Charge separation relative to the reaction plane in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV.

Physical review letters·2013
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Pharmacology
  • Drug Delivery Systems
  • Endocrinology

Background:

  • Non-insulin dependent diabetes mellitus (type II diabetes) affects millions globally.
  • Current insulin therapy primarily involves injections, which can be burdensome for patients.
  • Oral insulin delivery systems aim to improve patient compliance and convenience.

Purpose of the Study:

  • To evaluate the efficacy and safety of Macrulin, an oral insulin formulation, for type II diabetes treatment.
  • To assess the dose-related effects of oral insulin on blood glucose and serum insulin levels.
  • To investigate the pharmacokinetic profile of Macrulin in healthy volunteers.

Main Methods:

  • Phase IIa study in type II diabetic patients and Phase I studies in healthy volunteers.

Related Experiment Videos

  • Administration of Macrulin (oral insulin) via a tube into the small intestine.
  • Placebo-controlled crossover trials with blood glucose and serum insulin level monitoring.

    • Main Results:

    • Macrulin demonstrated a dose-related decrease in blood glucose and increase in serum insulin levels in type II diabetic patients.
    • No episodes of hypoglycemia were observed, even at the highest dose.
    • Phase I studies confirmed increased plasma insulin and decreased glucose levels after Macrulin administration.

    Conclusions:

    • Macrulin shows promise as an effective and safe oral insulin delivery system for type II diabetes.
    • The oral formulation offers a potential alternative to injectable insulin therapy.
    • Further clinical development is ongoing for this innovative treatment.